NEW YORK – Surface Oncology on Friday said it is collaborating with Roche to evaluate SRF388, an investigational anti-IL-27 antibody, in combination with Roche’s atezolizumab (Tecentriq) and bevacizumab (Avastin) in patients with treatment-naïve hepatocellular carcinoma.
Atezolizumab plus bevacizumab is considered a standard-of-care regimen in advanced liver cancer patients because it has shown to improve overall survival. Surface believes that combining SRF388 with this regimen can further improve outcomes in patients.
SRF388 inhibits the activity of IL-27, an immunosuppressive cytokine that immunosuppresses the tumor microenvironment and may play a role in hepatocellular carcinoma patients developing resistance to checkpoint inhibitors like atezolizumab. Surface said in a statement that it has identified a potential biomarker associated with IL-27 that may identify patients most likely to respond to SRF388.
“This collaboration leverages Roche’s deep experience in hepatocellular carcinoma and Surface’s commitment to rationally and rapidly develop SRF388, a first-in-class antibody against IL-27, to provide meaningful benefit to patients with liver cancer," Alison O'Neill, Surface's chief medical officer, said in a statement.
Last year, the US Food and Drug Administration granted SRF388 orphan drug designation and fast track status for the treatment of hepatocellular cancer.